Related Experiment Video
Updated: Aug 10, 2026
Forward Genetic Approaches in Chlamydia trachomatis
Published on: October 23, 2013
Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection
Eva Brandén1, Hirsh Koyi, Judy Gnarpe
1Department of Medicine, Karolinska Institutet, Stockholm, Sweden. eva.branden@karolinska.se
Abstract:
Chlamydia pneumoniae (Cpn) is a common respiratory pathogen with a biphasic replicative cycle and has a tendency to cause chronic infections. Azithromycin is commonly used for the treatment of Cpn infections, but little is known about the optimal dose and duration of therapy. In this prospective double-blind, randomized study the effects of azithromycin and placebo were compared regarding longstanding airway and/or pharyngeal symptoms in patients with chronic Cpn infection. Further, effects on antibody titres and lung function were assessed. 103 patients were treated with either azithromycin 500 mg daily for 5 d, repeated 3 times with a 23-d interval, or placebo. Patients were examined 4 months and 1 y after completed treatment. Evaluation of symptoms showed general improvement and less hawking in patients treated with azithromycin compared to placebo after 4 months, but there was no sustained difference 1 y after completed treatment. The antibody titres remained stable, and there was no influence on lung function. Adverse events, primarily gastrointestinal, were more frequently reported with azithromycin than placebo. In conclusion, azithromycin was effective for reduction of respiratory symptoms in patients with chronic Cpn infection, but prolonged intermittent treatment with high doses did not eradicate the chronic infection.
Insights
Azithromycin improved respiratory symptoms in chronic Chlamydia pneumoniae infections short-term. However, prolonged high-dose treatment did not eradicate the infection or provide lasting symptom relief.
Area of Science:
- Infectious Diseases
- Respiratory Medicine
- Pharmacology
Background:
- Chlamydia pneumoniae (Cpn) is a common respiratory pathogen.
- Cpn infections can become chronic, presenting challenges for treatment.
- Optimal azithromycin dosing for chronic Cpn infections is not well-established.
Purpose of the Study:
- To evaluate the efficacy of a specific azithromycin regimen for chronic Cpn infections.
- To assess the impact of treatment on airway/pharyngeal symptoms, antibody titers, and lung function.
- To compare azithromycin's effects against a placebo in a randomized, double-blind study.
Main Methods:
- 103 patients with chronic Cpn infection participated.
- Treatment involved azithromycin (500 mg daily for 5 days, repeated 3 times with 23-day intervals) or placebo.
- Patients were assessed at 4 months and 1 year post-treatment.
Main Results:
- Azithromycin showed a significant improvement in respiratory symptoms and reduced hawking at 4 months compared to placebo.
- Symptom improvement was not sustained at the 1-year follow-up.
- No significant changes were observed in antibody titers or lung function.
- Gastrointestinal adverse events were more common with azithromycin.
Conclusions:
- Azithromycin effectively reduced respiratory symptoms in the short term for chronic Cpn infections.
- The prolonged, intermittent high-dose regimen did not lead to eradication of chronic Cpn infection.
- Further research may be needed to determine optimal treatment strategies for chronic Cpn infections.
More Related Videos
06:49Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:23Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:29Bacterial Phylum Chlamydiae